Down_syndrome

Genetic MONDO:0008608 Pathograph 13 Chromosomal Disorder

A chromosomal disorder caused by trisomy 21, characterized by intellectual disability, distinctive facial features, hypotonia, and increased risk of congenital heart defects, hypothyroidism, and leukemia.

Ask OpenScientist

Ask a research question about Down_syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
11
Phenotypes
13
Pathograph
9
Genes
4
Treatments
2
References
2
Deep Research
⚙

Pathophysiology

6
Chromosome 21 Gene Dosage Imbalance
A supernumerary chromosome 21 increases dosage across more than 200 protein-coding genes, creating the upstream multi-system disturbance that drives the major Down syndrome phenotypes.
Downstream
Interferon Hyperactivation Triplication of chromosome 21 interferon receptor genes creates a constitutive interferon response.
Altered Neurogenesis and Astrogliogenesis Trisomy 21 perturbs developmental brain programs that favor gliogenesis over neuron production.
APP-Driven Alzheimer-like Neuropathology APP triplication on chromosome 21 accelerates age-dependent amyloid accumulation and downstream tau pathology.
Perturbed Fetal Erythro-Megakaryopoiesis Trisomy 21 expands fetal erythro-megakaryocytic progenitors that are vulnerable to leukemic transformation.
Show evidence (1 reference)
PMID:32029743 SUPPORT Other
"This endeavour is challenging, as there are >200 protein-coding genes on chromosome 21 and they can have direct and indirect effects on homeostasis in cells, tissues, organs and systems."
Establishes chromosome 21 gene dosage imbalance as the upstream cause of broad multi-organ dysregulation in Down syndrome.
Interferon Hyperactivation
Down syndrome cells show a chronic interferon program involving circulating immune cells and brain-resident microglia, with enhanced interferon-stimulated gene expression, abnormal synaptic pruning, and senescence-like microglial states.
monocyte link T cell link microglial cell link
type I interferon-mediated signaling pathway link cell surface receptor signaling pathway via JAK-STAT link
brain link
Downstream
Impaired Cardiogenesis Excess interferon signaling suppresses canonical Wnt signaling during cardiac differentiation.
Autoimmunity IFN-hyperactive T-cell remodeling promotes an autoimmune-prone immune state.
Show evidence (3 references)
PMID:27472900 SUPPORT In Vitro
"Using complementary genomics analyses, we identified the interferon pathway as the major signaling cascade consistently activated by trisomy 21 in human cells."
Demonstrates that interferon signaling is a reproducible upstream pathway activated by trisomy 21.
PMID:35803230 SUPPORT In Vitro
"Using induced pluripotent stem cell (iPSC)-based organoid and chimeric mouse models, we report that DS microglia exhibit an enhanced synaptic pruning function, which alters neuronal synaptic functions."
The combined organoid and chimeric mouse experiments include in vitro support that Down syndrome microglia show enhanced synaptic pruning and alter neuronal synaptic function.
PMID:35803230 SUPPORT Model Organism
"In response to human brain tissue-derived pathological tau, DS microglia undergo cellular senescence and exhibit elevated type-I-interferon signaling."
In vivo tau-challenge experiments in the paper support an interferon-linked senescent microglial state in Down syndrome microglia.
Impaired Cardiogenesis
Increased interferon receptor dosage in trisomy 21 represses canonical Wnt signaling and disrupts cardiac differentiation, providing a mechanism for the high burden of congenital heart defects.
cardiac muscle cell link
cardiac muscle cell differentiation link canonical Wnt signaling pathway link
heart link
Downstream
Congenital Heart Defects Disrupted cardiogenesis increases the likelihood of structural heart malformations in Down syndrome.
Show evidence (2 references)
PMID:37360690 SUPPORT In Vitro
"We differentiated human iPSCs derived from individuals with DS and CHDs, and healthy euploid controls into cardiac cells. We observed that T21 upregulates IFN signaling, downregulates the canonical WNT pathway, and impairs cardiac differentiation."
Human iPSC-based cardiac differentiation experiments support IFN signaling and Wnt suppression as a mechanism for abnormal cardiogenesis in Down syndrome.
PMID:37360690 SUPPORT Model Organism
"the Dp(16)1Yey/+ (Dp16) mouse model of DS, we identified downregulation of canonical Wnt signaling downstream of increased dosage of interferon (IFN) receptors (IFNRs) genes on chromosome 21 as a causative factor of cardiogenic dysregulation in DS."
The Dp16 mouse model supports IFN receptor dosage and Wnt suppression as a mechanism for abnormal cardiogenesis in Down syndrome.
Altered Neurogenesis and Astrogliogenesis
During Down syndrome brain development, astrocytes are overrepresented because differentiation shifts from neuron production toward astrocyte generation, with detrimental consequences for neural circuit formation.
astrocyte link neuron link
neurogenesis link astrocyte differentiation link
brain link
Downstream
Intellectual Disability Neurodevelopmental circuit abnormalities are a core substrate for lifelong intellectual disability.
Developmental Delay Widespread disturbances in brain development contribute to delayed acquisition of developmental milestones.
Show evidence (2 references)
PMID:39768129 SUPPORT Other
"In the DS brain, since the prenatal life stages, the number of astrocytes is disproportional compared to the healthy brain."
Supports abnormal astrocyte abundance as an early developmental feature of Down syndrome brain pathology.
PMID:39768129 SUPPORT Other
"This increase is due to a shift from neuron to astrocyte differentiation during brain development."
Provides direct support for altered lineage allocation from neurons toward astrocytes.
APP-Driven Alzheimer-like Neuropathology
APP overexpression from chromosome 21 drives lifelong amyloid-beta accumulation and age-dependent Alzheimer-like neuropathology in adults with Down syndrome, but plaque and tangle burden do not perfectly track with clinical dementia.
amyloid precursor protein metabolic process link
brain link
Downstream
Senile Plaques APP-driven amyloid accumulation produces Alzheimer-like neuritic plaque pathology.
Neurofibrillary Tangles Age-dependent tau aggregation produces neurofibrillary tangles in adult Down syndrome brain.
Show evidence (3 references)
PMID:30733618 SUPPORT Other
"Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer disease (AD) by the age of 40 years."
Supports the age-dependent near-universal emergence of Alzheimer-like neuropathology in adult Down syndrome.
PMID:30733618 SUPPORT Other
"This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21."
Supports APP dosage as a mechanistic driver of Alzheimer-like pathology in Down syndrome.
PMID:2149963 SUPPORT Human Clinical
"Clinical evidence of dementia and large numbers of SP and NFT were not always concordant."
Supports separating pathology-level findings from clinical Alzheimer disease or dementia in Down syndrome.
Perturbed Fetal Erythro-Megakaryopoiesis
Trisomy 21 expands fetal erythro-megakaryocytic progenitors early in life, increasing the pool of cells that can acquire GATA1 and cooperating lesions in transient abnormal myelopoiesis and ML-DS.
megakaryocyte-erythroid progenitor cell link
megakaryocyte differentiation link
Downstream
Leukemia Risk Abnormal fetal progenitor expansion and secondary GATA1 lesions raise the risk of childhood leukemia.
Show evidence (2 references)
PMID:18812473 SUPPORT In Vitro
"Our findings indicate that trisomy 21 itself is associated with cell-autonomous expansion of erythro-megakaryocytic progenitors."
Shows that trisomy 21 directly perturbs fetal hematopoiesis even before GATA1 mutation is acquired.
PMID:35483417 SUPPORT Other
"In the case of myeloid leukemias, the process of leukemogenesis in Trisomy 21 begins in early fetal life where genetic drivers including GATA1 mutations lead to the development of the preleukemic condition, transient abnormal myelopoiesis (TAM)."
Supports the fetal origin of GATA1-associated myeloid leukemogenesis in Down syndrome.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Down_syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Blood 1
Leukemia Risk OCCASIONAL Leukemia (HP:0001909)
Includes transient abnormal myelopoiesis/ML-DS and childhood ALL/AML, with the strongest excess risk for AML in early childhood.
Show evidence (1 reference)
PMID:33684394 SUPPORT Human Clinical
"Down syndrome remains a strong risk factor for childhood leukemia, and associations with AML are stronger than previously reported."
Confirms increased leukemia risk in children with Down syndrome.
Cardiovascular 1
Congenital Heart Defects FREQUENT Abnormal heart morphology (HP:0001627)
Show evidence (1 reference)
PMID:26504441 SUPPORT Human Clinical
"The prevalence of congenital heart disease in infants with Down syndrome is 40%, compared with 0.3% in children who have normal chromosomes."
Demonstrates high prevalence of congenital heart defects in Down syndrome.
Endocrine 1
Hypothyroidism FREQUENT Hypothyroidism (HP:0000821)
Show evidence (1 reference)
PMID:11853334 SUPPORT Human Clinical
"CONCLUSION: The prevalence of congenital hypothyroidism was 1.8% in children with Down's syndrome while 25.3% of them had compensated hypothyroidism."
Supports thyroid dysfunction, including hypothyroidism, as a common Down syndrome comorbidity.
Head and Neck 1
Dysmorphic Facial Features VERY_FREQUENT Upslanted palpebral fissure (HP:0000582)
Includes flat facial profile, slanted eyes, and a small nose.
Immune 1
Autoimmunity OCCASIONAL Autoimmunity (HP:0002960)
Associated with chronic interferon hyperactivation and immune dysregulation.
Show evidence (1 reference)
PMID:31699819 SUPPORT Human Clinical
"Trisomy 21 (T21) causes Down syndrome (DS), a condition characterized by high prevalence of autoimmune disorders."
Supports increased autoimmunity as part of the Down syndrome clinical spectrum.
Musculoskeletal 1
Hypotonia VERY_FREQUENT Hypotonia (HP:0001252)
Nervous System 5
Intellectual Disability VERY_FREQUENT Intellectual disability (HP:0001249)
Ranges from mild to moderate impairment.
Show evidence (1 reference)
PMID:39768129 SUPPORT Other
"Down syndrome (DS) is characterized by severe neurodevelopmental alterations that ultimately lead to the typical hallmark of DS: intellectual disability."
Directly supports intellectual disability as a core Down syndrome phenotype arising from abnormal brain development.
Developmental Delay VERY_FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
PMID:26924435 SUPPORT Human Clinical
"Trisomy 21, or Down syndrome (DS), is the most common genetic cause of developmental delay and intellectual disability."
Supports developmental delay as a major neurodevelopmental phenotype of Down syndrome.
Sleep Apnea FREQUENT Obstructive sleep apnea (HP:0002870)
Show evidence (1 reference)
PMID:14746382 SUPPORT Human Clinical
"CONCLUSIONS: The prevalence of sleep-disordered breathing in children with Down syndrome is very high, particularly in boys."
Supports obstructive sleep apnea and related sleep-disordered breathing as common respiratory manifestations in Down syndrome.
Senile Plaques Senile plaques (HP:0100256)
Alzheimer-like plaque pathology is common in adult Down syndrome and can precede clinical dementia.
Show evidence (3 references)
PMID:2149963 SUPPORT Human Clinical
"Patients with Down syndrome (DS) over 40 years of age, prematurely and consistently develop neurofibrillary tangles (NFT), intracytoplasmic inclusions of highly insoluble straight or paired helical 12-16 nm filaments, and senile plaques (SP) composed of abnormal neurites surrounding a core of..."
Supports senile plaques as a characteristic adult neuropathological finding in Down syndrome.
PMID:3159974 SUPPORT Human Clinical
"The morphometric observations of the brains of these seven patients with AD showed that the numbers of plaques and tangles exceeded 20 per 1.5 X 10(6) microns2 area, in both the prefrontal and hippocampal cortices."
Supports substantial plaque burden in adults with Down syndrome and Alzheimer-type dementia.
PMID:2149963 SUPPORT Human Clinical
"Clinical evidence of dementia and large numbers of SP and NFT were not always concordant."
Supports using a pathology-level phenotype rather than equating plaques with clinical Alzheimer disease.
Neurofibrillary Tangles Neurofibrillary tangles (HP:0002185)
Tau tangle pathology in Down syndrome should be distinguished from clinical Alzheimer disease or dementia.
Show evidence (3 references)
PMID:2149963 SUPPORT Human Clinical
"Patients with Down syndrome (DS) over 40 years of age, prematurely and consistently develop neurofibrillary tangles (NFT), intracytoplasmic inclusions of highly insoluble straight or paired helical 12-16 nm filaments, and senile plaques (SP) composed of abnormal neurites surrounding a core of..."
Supports neurofibrillary tangles as a characteristic adult neuropathological finding in Down syndrome.
PMID:3159974 SUPPORT Human Clinical
"The morphometric observations of the brains of these seven patients with AD showed that the numbers of plaques and tangles exceeded 20 per 1.5 X 10(6) microns2 area, in both the prefrontal and hippocampal cortices."
Supports substantial neurofibrillary tangle burden in adults with Down syndrome and Alzheimer-type dementia.
PMID:2149963 SUPPORT Human Clinical
"Clinical evidence of dementia and large numbers of SP and NFT were not always concordant."
Supports using a pathology-level phenotype rather than equating tangles with clinical Alzheimer disease.
🧬

Genetic Associations

9
Trisomy 21 (Causal)
Show evidence (1 reference)
PMID:32029743 SUPPORT Other
"Trisomy 21, the presence of a supernumerary chromosome 21, results in a collection of clinical features commonly known as Down syndrome (DS)."
Directly supports trisomy 21 as the causal genetic lesion underlying Down syndrome.
APP (Risk Factor)
Show evidence (2 references)
PMID:30733618 SUPPORT Other
"This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21."
Supports APP dosage as a driver of Alzheimer-like neuropathology in Down syndrome.
PMID:1671712 PARTIAL Human Clinical
"This suggests that some cases of AD could be caused by mutations in the APP gene."
Indirectly supports APP as a causal driver of Alzheimer pathology, strengthening the mechanistic plausibility that APP triplication contributes to Down syndrome Alzheimer-like neuropathology.
GATA1 (Somatic preleukemic mutation)
Show evidence (1 reference)
PMID:35483417 SUPPORT Other
"In the case of myeloid leukemias, the process of leukemogenesis in Trisomy 21 begins in early fetal life where genetic drivers including GATA1 mutations lead to the development of the preleukemic condition, transient abnormal myelopoiesis (TAM)."
Supports GATA1 mutation as a key cooperating lesion in Down syndrome-associated myeloid leukemogenesis.
DYRK1A (Risk Factor)
IFNAR1 (Risk Factor)
IFNAR2 (Risk Factor)
IFNGR2 (Risk Factor)
IL10RB (Risk Factor)
OLIG2 (Risk Factor)
💊

Treatments

4
Early Intervention Programs
Action: behavioral counseling MAXO:0000077
Support services including physical, occupational, and speech therapy.
Show evidence (1 reference)
PMID:32029743 NO_EVIDENCE
"Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored; these efforts provide reasonable hope for the future."
Supports importance of therapeutic interventions for intellectual disability in Down syndrome.
Cardiac Surgery
Action: surgical procedure MAXO:0000004
For congenital heart defect correction if needed.
Show evidence (1 reference)
PMID:32029743 NO_EVIDENCE
"Since the first description of trisomy 21, we have learned much about intellectual disability and genetic risk factors for congenital heart disease."
Supports the association of congenital heart disease with Down syndrome requiring surgical intervention.
Hormone Replacement Therapy
Action: hormone modifying therapy MAXO:0000283
For treating hypothyroidism.
Show evidence (1 reference)
PMID:11853334 NO_EVIDENCE
"Down's syndrome patients with normal thyroid functions and those with compensated hypothyroidism should be followed annually and every 3 mo, respectively."
Snippet supports monitoring intervals, but does not directly support hormone replacement therapy.
Educational Support
Action: behavioral counseling MAXO:0000077
Tailored educational plans to support learning and development.
Show evidence (1 reference)
PMID:32029743 NO_EVIDENCE
"Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored."
Snippet discusses exploratory clinical interventions broadly, not educational support specifically.
🌍

Environmental Factors

1
Prenatal Screening
Screening tests are available to evaluate the risk of Down syndrome before birth.
🔬

Biochemical Markers

1
TSH (Thyroid-Stimulating Hormone) (Elevated)
Context: Indicates hypothyroidism
Show evidence (1 reference)
PMID:11853334 SUPPORT Human Clinical
"Sixteen of the remaining 81 patients (25.3%) had compensated hypothyroidism with increased thyroid-stimulating hormone (TSH) levels (11-20 mU l(-1))."
Supports elevated TSH as a common biochemical correlate of compensated hypothyroidism in Down syndrome.
{ }

Source YAML

click to show 
name: Down_syndrome
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-10T01:38:32Z'
description: A chromosomal disorder caused by trisomy 21, characterized by intellectual disability, distinctive facial features, hypotonia, and increased risk of congenital heart defects, hypothyroidism, and leukemia.
category: Genetic
parents:
- Chromosomal Disorder
synonyms:
- Trisomy 21
prevalence:
- population: Global
  percentage: 0.1
pathophysiology:
- name: Chromosome 21 Gene Dosage Imbalance
  description: >
    A supernumerary chromosome 21 increases dosage across more than 200
    protein-coding genes, creating the upstream multi-system disturbance that
    drives the major Down syndrome phenotypes.
  evidence:
  - reference: PMID:32029743
    reference_title: "Down syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This endeavour is challenging, as there are >200 protein-coding genes on chromosome 21 and they can have direct and indirect effects on homeostasis in cells, tissues, organs and systems."
    explanation: Establishes chromosome 21 gene dosage imbalance as the upstream cause of broad multi-organ dysregulation in Down syndrome.
  downstream:
  - target: Interferon Hyperactivation
    description: Triplication of chromosome 21 interferon receptor genes creates a constitutive interferon response.
    evidence:
    - reference: PMID:27472900
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Therefore, we propose that interferon activation, likely via increased gene dosage of the four interferon receptors encoded on chromosome 21, contributes to many of the clinical impacts of trisomy 21, and that interferon antagonists could have therapeutic benefits."
      explanation: Links chromosome 21 dosage directly to interferon receptor overexpression and chronic interferon activation.
  - target: Altered Neurogenesis and Astrogliogenesis
    description: Trisomy 21 perturbs developmental brain programs that favor gliogenesis over neuron production.
    evidence:
    - reference: PMID:39768129
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "This increase is due to a shift from neuron to astrocyte differentiation during brain development."
      explanation: Supports a trisomy-linked developmental bias from neurogenesis toward astrogliogenesis.
  - target: APP-Driven Alzheimer-like Neuropathology
    description: APP triplication on chromosome 21 accelerates age-dependent amyloid accumulation and downstream tau pathology.
    evidence:
    - reference: PMID:30733618
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21."
      explanation: Supports APP dosage as a mechanistic bridge between trisomy 21 and Alzheimer-like neuropathology in Down syndrome.
  - target: Perturbed Fetal Erythro-Megakaryopoiesis
    description: Trisomy 21 expands fetal erythro-megakaryocytic progenitors that are vulnerable to leukemic transformation.
    evidence:
    - reference: PMID:18812473
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Our findings indicate that trisomy 21 itself is associated with cell-autonomous expansion of erythro-megakaryocytic progenitors."
      explanation: Supports trisomy 21 as a direct driver of abnormal fetal hematopoietic progenitor expansion.
- name: Interferon Hyperactivation
  description: >
    Down syndrome cells show a chronic interferon program involving circulating
    immune cells and brain-resident microglia, with enhanced
    interferon-stimulated gene expression, abnormal synaptic pruning, and
    senescence-like microglial states.
  cell_types:
  - preferred_term: monocyte
    term:
      id: CL:0000576
      label: monocyte
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: type I interferon-mediated signaling pathway
    term:
      id: GO:0060337
      label: type I interferon-mediated signaling pathway
  - preferred_term: cell surface receptor signaling pathway via JAK-STAT
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:27472900
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using complementary genomics analyses, we identified the interferon pathway as the major signaling cascade consistently activated by trisomy 21 in human cells."
    explanation: Demonstrates that interferon signaling is a reproducible upstream pathway activated by trisomy 21.
  - reference: PMID:35803230
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using induced pluripotent stem cell (iPSC)-based organoid and chimeric mouse models, we report that DS microglia exhibit an enhanced synaptic pruning function, which alters neuronal synaptic functions."
    explanation: The combined organoid and chimeric mouse experiments include in vitro support that Down syndrome microglia show enhanced synaptic pruning and alter neuronal synaptic function.
  - reference: PMID:35803230
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In response to human brain tissue-derived pathological tau, DS microglia undergo cellular senescence and exhibit elevated type-I-interferon signaling."
    explanation: In vivo tau-challenge experiments in the paper support an interferon-linked senescent microglial state in Down syndrome microglia.
  downstream:
  - target: Impaired Cardiogenesis
    description: Excess interferon signaling suppresses canonical Wnt signaling during cardiac differentiation.
    evidence:
    - reference: PMID:37360690
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We differentiated human iPSCs derived from individuals with DS and CHDs, and healthy euploid controls into cardiac cells. We observed that T21 upregulates IFN signaling, downregulates the canonical WNT pathway, and impairs cardiac differentiation."
      explanation: Human iPSC differentiation experiments connect interferon hyperactivity directly to defective cardiogenesis in Down syndrome.
  - target: Autoimmunity
    description: IFN-hyperactive T-cell remodeling promotes an autoimmune-prone immune state.
    evidence:
    - reference: PMID:31699819
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Therefore, these results point to T cell dysregulation associated with IFN hyperactivity as a contributor to autoimmunity in DS."
      explanation: Supports interferon-linked T-cell dysregulation as a mechanistic contributor to autoimmunity in Down syndrome.
- name: Impaired Cardiogenesis
  description: >
    Increased interferon receptor dosage in trisomy 21 represses canonical Wnt
    signaling and disrupts cardiac differentiation, providing a mechanism for
    the high burden of congenital heart defects.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: cardiac muscle cell differentiation
    term:
      id: GO:0055007
      label: cardiac muscle cell differentiation
  - preferred_term: canonical Wnt signaling pathway
    term:
      id: GO:0060070
      label: canonical Wnt signaling pathway
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:37360690
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We differentiated human iPSCs derived from individuals with DS and CHDs, and healthy euploid controls into cardiac cells. We observed that T21 upregulates IFN signaling, downregulates the canonical WNT pathway, and impairs cardiac differentiation."
    explanation: Human iPSC-based cardiac differentiation experiments support IFN signaling and Wnt suppression as a mechanism for abnormal cardiogenesis in Down syndrome.
  - reference: PMID:37360690
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the Dp(16)1Yey/+ (Dp16) mouse model of DS, we identified downregulation of canonical Wnt signaling downstream of increased dosage of interferon (IFN) receptors (IFNRs) genes on chromosome 21 as a causative factor of cardiogenic dysregulation in DS."
    explanation: The Dp16 mouse model supports IFN receptor dosage and Wnt suppression as a mechanism for abnormal cardiogenesis in Down syndrome.
  downstream:
  - target: Congenital Heart Defects
    description: Disrupted cardiogenesis increases the likelihood of structural heart malformations in Down syndrome.
    evidence:
    - reference: PMID:26504441
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The prevalence of congenital heart disease in infants with Down syndrome is 40%, compared with 0.3% in children who have normal chromosomes."
      explanation: Clinical cohort data confirm congenital heart disease as a common downstream manifestation in Down syndrome.
- name: Altered Neurogenesis and Astrogliogenesis
  description: >
    During Down syndrome brain development, astrocytes are overrepresented
    because differentiation shifts from neuron production toward astrocyte
    generation, with detrimental consequences for neural circuit formation.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neurogenesis
    term:
      id: GO:0022008
      label: neurogenesis
  - preferred_term: astrocyte differentiation
    term:
      id: GO:0048708
      label: astrocyte differentiation
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:39768129
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the DS brain, since the prenatal life stages, the number of astrocytes is disproportional compared to the healthy brain."
    explanation: Supports abnormal astrocyte abundance as an early developmental feature of Down syndrome brain pathology.
  - reference: PMID:39768129
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This increase is due to a shift from neuron to astrocyte differentiation during brain development."
    explanation: Provides direct support for altered lineage allocation from neurons toward astrocytes.
  downstream:
  - target: Intellectual Disability
    description: Neurodevelopmental circuit abnormalities are a core substrate for lifelong intellectual disability.
    evidence:
    - reference: PMID:39768129
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Down syndrome (DS) is characterized by severe neurodevelopmental alterations that ultimately lead to the typical hallmark of DS: intellectual disability."
      explanation: Directly links neurodevelopmental alterations in Down syndrome to intellectual disability.
  - target: Developmental Delay
    description: Widespread disturbances in brain development contribute to delayed acquisition of developmental milestones.
    evidence:
    - reference: PMID:26924435
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Trisomy 21, or Down syndrome (DS), is the most common genetic cause of developmental delay and intellectual disability."
      explanation: Supports developmental delay as a major downstream neurodevelopmental manifestation of trisomy 21.
- name: APP-Driven Alzheimer-like Neuropathology
  description: >
    APP overexpression from chromosome 21 drives lifelong amyloid-beta
    accumulation and age-dependent Alzheimer-like neuropathology in adults with
    Down syndrome, but plaque and tangle burden do not perfectly track with
    clinical dementia.
  biological_processes:
  - preferred_term: amyloid precursor protein metabolic process
    term:
      id: GO:0042982
      label: amyloid precursor protein metabolic process
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:30733618
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer disease (AD) by the age of 40 years."
    explanation: Supports the age-dependent near-universal emergence of Alzheimer-like neuropathology in adult Down syndrome.
  - reference: PMID:30733618
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21."
    explanation: Supports APP dosage as a mechanistic driver of Alzheimer-like pathology in Down syndrome.
  - reference: PMID:2149963
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical evidence of dementia and large numbers of SP and NFT were not always concordant."
    explanation: Supports separating pathology-level findings from clinical Alzheimer disease or dementia in Down syndrome.
  downstream:
  - target: Senile Plaques
    description: APP-driven amyloid accumulation produces Alzheimer-like neuritic plaque pathology.
    evidence:
    - reference: PMID:2149963
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with Down syndrome (DS) over 40 years of age, prematurely and consistently develop neurofibrillary tangles (NFT), intracytoplasmic inclusions of highly insoluble straight or paired helical 12-16 nm filaments, and senile plaques (SP) composed of abnormal neurites surrounding a core of beta amyloid."
      explanation: Supports senile plaques as a characteristic adult neuropathological finding in Down syndrome.
  - target: Neurofibrillary Tangles
    description: Age-dependent tau aggregation produces neurofibrillary tangles in adult Down syndrome brain.
    evidence:
    - reference: PMID:2149963
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients with Down syndrome (DS) over 40 years of age, prematurely and consistently develop neurofibrillary tangles (NFT), intracytoplasmic inclusions of highly insoluble straight or paired helical 12-16 nm filaments, and senile plaques (SP) composed of abnormal neurites surrounding a core of beta amyloid."
      explanation: Supports neurofibrillary tangles as a characteristic adult neuropathological finding in Down syndrome.
- name: Perturbed Fetal Erythro-Megakaryopoiesis
  description: >
    Trisomy 21 expands fetal erythro-megakaryocytic progenitors early in life,
    increasing the pool of cells that can acquire GATA1 and cooperating lesions
    in transient abnormal myelopoiesis and ML-DS.
  cell_types:
  - preferred_term: megakaryocyte-erythroid progenitor cell
    term:
      id: CL:0000050
      label: megakaryocyte-erythroid progenitor cell
  biological_processes:
  - preferred_term: megakaryocyte differentiation
    term:
      id: GO:0030219
      label: megakaryocyte differentiation
  evidence:
  - reference: PMID:18812473
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our findings indicate that trisomy 21 itself is associated with cell-autonomous expansion of erythro-megakaryocytic progenitors."
    explanation: Shows that trisomy 21 directly perturbs fetal hematopoiesis even before GATA1 mutation is acquired.
  - reference: PMID:35483417
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the case of myeloid leukemias, the process of leukemogenesis in Trisomy 21 begins in early fetal life where genetic drivers including GATA1 mutations lead to the development of the preleukemic condition, transient abnormal myelopoiesis (TAM)."
    explanation: Supports the fetal origin of GATA1-associated myeloid leukemogenesis in Down syndrome.
  downstream:
  - target: Leukemia Risk
    description: Abnormal fetal progenitor expansion and secondary GATA1 lesions raise the risk of childhood leukemia.
    evidence:
    - reference: PMID:18812473
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "This may predispose to TMD and AMKL by increasing the pool of cells susceptible to malignant transformation through acquired mutations in GATA1 and other cooperating genes."
      explanation: Supports abnormal fetal erythro-megakaryocytic expansion as a mechanistic basis for leukemia predisposition in Down syndrome.
phenotypes:
- category: Craniofacial
  name: Dysmorphic Facial Features
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Includes flat facial profile, slanted eyes, and a small nose.
  phenotype_term:
    preferred_term: Upslanted palpebral fissure
    term:
      id: HP:0000582
      label: Upslanted palpebral fissure
- category: Neurologic
  name: Intellectual Disability
  frequency: VERY_FREQUENT
  notes: Ranges from mild to moderate impairment.
  phenotype_term:
    preferred_term: Intellectual Disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:39768129
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Down syndrome (DS) is characterized by severe neurodevelopmental alterations that ultimately lead to the typical hallmark of DS: intellectual disability."
    explanation: Directly supports intellectual disability as a core Down syndrome phenotype arising from abnormal brain development.
- category: Developmental
  name: Developmental Delay
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Developmental Delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:26924435
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Trisomy 21, or Down syndrome (DS), is the most common genetic cause of developmental delay and intellectual disability."
    explanation: Supports developmental delay as a major neurodevelopmental phenotype of Down syndrome.
- category: Musculoskeletal
  name: Hypotonia
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
- category: Cardiac
  name: Congenital Heart Defects
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:26504441
    reference_title: "Down Syndrome with Complete Atrioventricular Septal Defect, Hypertrophic Cardiomyopathy, and Pulmonary Vein Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of congenital heart disease in infants with Down syndrome is 40%, compared with 0.3% in children who have normal chromosomes."
    explanation: Demonstrates high prevalence of congenital heart defects in Down syndrome.
- category: Endocrine
  name: Hypothyroidism
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  evidence:
  - reference: PMID:11853334
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CONCLUSION: The prevalence of congenital hypothyroidism was 1.8% in children with Down's syndrome while 25.3% of them had compensated hypothyroidism."
    explanation: Supports thyroid dysfunction, including hypothyroidism, as a common Down syndrome comorbidity.
- category: Hematologic
  name: Leukemia Risk
  frequency: OCCASIONAL
  notes: Includes transient abnormal myelopoiesis/ML-DS and childhood ALL/AML, with the strongest excess risk for AML in early childhood.
  phenotype_term:
    preferred_term: Leukemia
    term:
      id: HP:0001909
      label: Leukemia
  evidence:
  - reference: PMID:33684394
    reference_title: "Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Down syndrome remains a strong risk factor for childhood leukemia, and associations with AML are stronger than previously reported."
    explanation: Confirms increased leukemia risk in children with Down syndrome.
- category: Respiratory
  name: Sleep Apnea
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Sleep Apnea
    term:
      id: HP:0002870
      label: Obstructive sleep apnea
  evidence:
  - reference: PMID:14746382
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CONCLUSIONS: The prevalence of sleep-disordered breathing in children with Down syndrome is very high, particularly in boys."
    explanation: Supports obstructive sleep apnea and related sleep-disordered breathing as common respiratory manifestations in Down syndrome.
- category: Immunologic
  name: Autoimmunity
  frequency: OCCASIONAL
  notes: Associated with chronic interferon hyperactivation and immune dysregulation.
  phenotype_term:
    preferred_term: Autoimmunity
    term:
      id: HP:0002960
      label: Autoimmunity
  evidence:
  - reference: PMID:31699819
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Trisomy 21 (T21) causes Down syndrome (DS), a condition characterized by high prevalence of autoimmune disorders."
    explanation: Supports increased autoimmunity as part of the Down syndrome clinical spectrum.
- category: Neuropathological
  name: Senile Plaques
  context: Adults older than 40 years
  notes: Alzheimer-like plaque pathology is common in adult Down syndrome and can precede clinical dementia.
  phenotype_term:
    preferred_term: Senile plaques
    term:
      id: HP:0100256
      label: Senile plaques
  evidence:
  - reference: PMID:2149963
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with Down syndrome (DS) over 40 years of age, prematurely and consistently develop neurofibrillary tangles (NFT), intracytoplasmic inclusions of highly insoluble straight or paired helical 12-16 nm filaments, and senile plaques (SP) composed of abnormal neurites surrounding a core of beta amyloid."
    explanation: Supports senile plaques as a characteristic adult neuropathological finding in Down syndrome.
  - reference: PMID:3159974
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The morphometric observations of the brains of these seven patients with AD showed that the numbers of plaques and tangles exceeded 20 per 1.5 X 10(6) microns2 area, in both the prefrontal and hippocampal cortices."
    explanation: Supports substantial plaque burden in adults with Down syndrome and Alzheimer-type dementia.
  - reference: PMID:2149963
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical evidence of dementia and large numbers of SP and NFT were not always concordant."
    explanation: Supports using a pathology-level phenotype rather than equating plaques with clinical Alzheimer disease.
- category: Neuropathological
  name: Neurofibrillary Tangles
  context: Adults older than 40 years
  notes: Tau tangle pathology in Down syndrome should be distinguished from clinical Alzheimer disease or dementia.
  phenotype_term:
    preferred_term: Neurofibrillary tangles
    term:
      id: HP:0002185
      label: Neurofibrillary tangles
  evidence:
  - reference: PMID:2149963
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with Down syndrome (DS) over 40 years of age, prematurely and consistently develop neurofibrillary tangles (NFT), intracytoplasmic inclusions of highly insoluble straight or paired helical 12-16 nm filaments, and senile plaques (SP) composed of abnormal neurites surrounding a core of beta amyloid."
    explanation: Supports neurofibrillary tangles as a characteristic adult neuropathological finding in Down syndrome.
  - reference: PMID:3159974
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The morphometric observations of the brains of these seven patients with AD showed that the numbers of plaques and tangles exceeded 20 per 1.5 X 10(6) microns2 area, in both the prefrontal and hippocampal cortices."
    explanation: Supports substantial neurofibrillary tangle burden in adults with Down syndrome and Alzheimer-type dementia.
  - reference: PMID:2149963
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical evidence of dementia and large numbers of SP and NFT were not always concordant."
    explanation: Supports using a pathology-level phenotype rather than equating tangles with clinical Alzheimer disease.
biochemical:
- name: TSH (Thyroid-Stimulating Hormone)
  presence: Elevated
  context: Indicates hypothyroidism
  evidence:
  - reference: PMID:11853334
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sixteen of the remaining 81 patients (25.3%) had compensated hypothyroidism with increased thyroid-stimulating hormone (TSH) levels (11-20 mU l(-1))."
    explanation: Supports elevated TSH as a common biochemical correlate of compensated hypothyroidism in Down syndrome.
genetic:
- name: Trisomy 21
  association: Causal
  notes: Presence of an extra copy of chromosome 21 is the defining genetic lesion in Down syndrome.
  evidence:
  - reference: PMID:32029743
    reference_title: "Down syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Trisomy 21, the presence of a supernumerary chromosome 21, results in a collection of clinical features commonly known as Down syndrome (DS)."
    explanation: Directly supports trisomy 21 as the causal genetic lesion underlying Down syndrome.
- name: APP
  association: Risk Factor
  notes: Dosage of APP on chromosome 21 contributes to age-dependent amyloid-beta accumulation and Alzheimer-like neuropathology in adults with Down syndrome.
  evidence:
  - reference: PMID:30733618
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21."
    explanation: Supports APP dosage as a driver of Alzheimer-like neuropathology in Down syndrome.
  - reference: PMID:1671712
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "This suggests that some cases of AD could be caused by mutations in the APP gene."
    explanation: Indirectly supports APP as a causal driver of Alzheimer pathology, strengthening the mechanistic plausibility that APP triplication contributes to Down syndrome Alzheimer-like neuropathology.
- name: GATA1
  association: Somatic preleukemic mutation
  notes: Acquired GATA1 mutations in trisomy 21 fetal progenitors drive transient abnormal myelopoiesis and ML-DS.
  evidence:
  - reference: PMID:35483417
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the case of myeloid leukemias, the process of leukemogenesis in Trisomy 21 begins in early fetal life where genetic drivers including GATA1 mutations lead to the development of the preleukemic condition, transient abnormal myelopoiesis (TAM)."
    explanation: Supports GATA1 mutation as a key cooperating lesion in Down syndrome-associated myeloid leukemogenesis.
- name: DYRK1A
  association: Risk Factor
  notes: Dual-specificity tyrosine-phosphorylation-regulated kinase 1A on chromosome 21; triplication perturbs neurodevelopment and contributes to intellectual disability.
- name: IFNAR1
  association: Risk Factor
  notes: Interferon alpha/beta receptor 1 on chromosome 21; triplication contributes to interferon hyperactivation.
- name: IFNAR2
  association: Risk Factor
  notes: Interferon alpha/beta receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.
- name: IFNGR2
  association: Risk Factor
  notes: Interferon gamma receptor 2 on chromosome 21; triplication contributes to interferon hyperactivation.
- name: IL10RB
  association: Risk Factor
  notes: Interleukin 10 receptor subunit beta on chromosome 21; triplication contributes to interferon hyperactivation.
- name: OLIG2
  association: Risk Factor
  notes: Oligodendrocyte transcription factor 2; overexpression shifts neurogenesis toward astrogliogenesis, reducing neuronal output.
diagnosis:
- name: Karyotype Analysis
  presence: 47,XX,+21 or 47,XY,+21
environmental:
- name: Prenatal Screening
  description: Screening tests are available to evaluate the risk of Down syndrome before birth.
treatments:
- name: Early Intervention Programs
  description: Support services including physical, occupational, and speech therapy.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
  evidence:
  - reference: PMID:32029743
    reference_title: "Down syndrome."
    supports: NO_EVIDENCE
    snippet: "Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored; these efforts provide reasonable hope for the future."
    explanation: Supports importance of therapeutic interventions for intellectual disability in Down syndrome.
- name: Cardiac Surgery
  description: For congenital heart defect correction if needed.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:32029743
    reference_title: "Down syndrome."
    supports: NO_EVIDENCE
    snippet: "Since the first description of trisomy 21, we have learned much about intellectual disability and genetic risk factors for congenital heart disease."
    explanation: Supports the association of congenital heart disease with Down syndrome requiring surgical intervention.
- name: Hormone Replacement Therapy
  description: For treating hypothyroidism.
  treatment_term:
    preferred_term: hormone modifying therapy
    term:
      id: MAXO:0000283
      label: hormone modifying therapy
  evidence:
  - reference: PMID:11853334
    reference_title: "Thyroid dysfunction in children with Down's syndrome."
    supports: NO_EVIDENCE
    snippet: "Down's syndrome patients with normal thyroid functions and those with compensated hypothyroidism should be followed annually and every 3 mo, respectively."
    explanation: Snippet supports monitoring intervals, but does not directly support hormone replacement therapy.
- name: Educational Support
  description: Tailored educational plans to support learning and development.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
  evidence:
  - reference: PMID:32029743
    reference_title: "Down syndrome."
    supports: NO_EVIDENCE
    snippet: "Clinical trials to ameliorate intellectual disability in DS signal a new era in which therapeutic interventions based on knowledge of the molecular pathophysiology of DS can now be explored."
    explanation: Snippet discusses exploratory clinical interventions broadly, not educational support specifically.
references:
- reference: PMID:3159974
  title: "Alzheimer's disease in Down's syndrome: clinicopathologic studies."
  findings:
  - statement: In seven Down syndrome patients older than 40 years, clinical and neuropathologic evidence supported Alzheimer disease with progressive dementia over 2.5 to 9.2 years.
    supporting_text: "Clinical and neuropathologic evidence points to the development of Alzheimer's disease (AD) in seven Down's syndrome patients above age 40. Dementia was observed in these patients over periods of 2.5 to 9.2 years."
  - statement: In those brains, plaques and tangles were abundant in prefrontal and hippocampal cortices and were also evident in deeper brain regions.
    supporting_text: "The morphometric observations of the brains of these seven patients with AD showed that the numbers of plaques and tangles exceeded 20 per 1.5 X 10(6) microns2 area, in both the prefrontal and hippocampal cortices. Plaques and tangles were also evident in the basal ganglia, thalamus, hypothalamus, and midbrain."
- reference: PMID:1671712
  title: "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease."
  findings:
  - statement: In a chromosome 21-linked familial Alzheimer disease kindred, the study identified a point mutation in APP.
    supporting_text: "Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene."
  - statement: The paper concluded that some Alzheimer disease cases could be caused by APP mutations.
    supporting_text: "This suggests that some cases of AD could be caused by mutations in the APP gene."
review_notes: Down syndrome, also known as Trisomy 21, is associated with a characteristic set of phenotypes and increased risk for certain medical conditions. Early intervention and supportive care improve quality of life.
disease_term:
  preferred_term: Down syndrome
  term:
    id: MONDO:0008608
    label: Down syndrome
📚

References & Deep Research

References

2
PMID:3159974
Alzheimer's disease in Down's syndrome: clinicopathologic studies.
2 findings
In seven Down syndrome patients older than 40 years, clinical and neuropathologic evidence supported Alzheimer disease with progressive dementia over 2.5 to 9.2 years.
"Clinical and neuropathologic evidence points to the development of Alzheimer's disease (AD) in seven Down's syndrome patients above age 40. Dementia was observed in these patients over periods of 2.5 to 9.2 years."
In those brains, plaques and tangles were abundant in prefrontal and hippocampal cortices and were also evident in deeper brain regions.
"The morphometric observations of the brains of these seven patients with AD showed that the numbers of plaques and tangles exceeded 20 per 1.5 X 10(6) microns2 area, in both the prefrontal and hippocampal cortices. Plaques and tangles were also evident in the basal ganglia, thalamus,..."
PMID:1671712
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.
2 findings
In a chromosome 21-linked familial Alzheimer disease kindred, the study identified a point mutation in APP.
"Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene."
The paper concluded that some Alzheimer disease cases could be caused by APP mutations.
"This suggests that some cases of AD could be caused by mutations in the APP gene."

Deep Research

2
Disorder ▸

Disorder

  • Name: Down_syndrome
  • Category: Genetic
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 15

Key Pathophysiology Nodes

  • Extra Chromosome 21
  • Interferon Hyperactivation
  • Neurodevelopmental Alterations
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1016/j.isci.2025.113130
  • DOI:10.1038/s41583-024-00866-2
  • DOI:10.1101/2025.06.30.662385
  • DOI:10.1126/sciadv.adg6218
  • DOI:10.3390/cells13242037
  • DOI:10.7554/elife.89763.3
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 19 citations 2025-12-15T09:08:15.769113

Disease Pathophysiology Research Report

Target Disease - Disease Name: Down syndrome (trisomy 21) - MONDO ID: MONDO:0000508 - Category: Genetic

Pathophysiology overview (current understanding) Down syndrome (DS) is caused by constitutive trisomy of human chromosome 21 (Hsa21). Contemporary multi-omic and single-cell studies converge on several mechanistic pillars: dosage effects of Hsa21 genes drive chronic interferon (IFN) pathway hyperactivation and JAK–STAT signaling (“interferonopathy”), broad immune remodeling, altered neurodevelopment with neuron-to-astrocyte fate shifts and microglial activation, and metabolic stress pathways including redox and tryptophan–kynurenine dysregulation. These processes interact with APP gene dose to produce near-universal Alzheimer-like neuropathology in adulthood, with microglia- and IFN-linked inflammation shaping amyloid/tau pathophysiology. Modulation of JAK–STAT signaling normalizes IFN signatures in people with DS and rescues inflammatory gene programs and cognition in DS–AD mouse models, motivating trials of immune-modulatory strategies in DS. (galbraith2023multidimensionaldefinitionof pages 1-2, araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18)

  • IFN/JAK‑STAT: "constitutive hyperactivation of interferon signaling" in trisomy 21 is driven in part by triplication of IFN receptor genes on chr21; "JAK inhibition normalizes interferon signatures" (galbraith2023multidimensionaldefinitionof pages 1-2, araya2025interferonsignalingmodulates pages 1-3)
  • DS→AD links: APP dose effect produces early amyloid pathology and DS‑AD features; spatial transcriptomics and microglial activation link IFN/inflammation to accelerated amyloid/tau, and systemic JAK inhibition rescued inflammatory gene expression and cognition in a DS‑AD mouse model (araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18)
  • Neurodevelopmental defects: reduced neurogenesis, progenitor cell‑cycle dysregulation, OLIG2 overexpression driving gliogenesis at the expense of neurons, and persistent dendritic/spine deficits that impair circuit formation ("shift from neuron to astrocyte differentiation") (russo2024consequencesoftrisomy pages 17-18, uguagliati2024astrocyticalterationsand pages 1-2)
  • Glia & complement: increased astrocyte numbers, reactive microglial / disease‑associated microglia states, and complement pathway dysregulation accompany neuroinflammation and synaptic alterations in DS (uguagliati2024astrocyticalterationsand pages 1-2, galbraith2023multidimensionaldefinitionof pages 1-2)
  • Mitochondria & metabolism: mitochondrial dysfunction, oxidative stress and altered metabolic pathways (notably tryptophan→kynurenine dysregulation linked to neurotoxic catabolites) are recurrent features in DS and correlate with amyloid burden and cognitive decline (galbraith2023multidimensionaldefinitionof pages 1-2, risgaard2025molecularandcellular pages 31-33)
  • Airway/epithelia antiviral responses: recent preclinical/clinical reports describe impaired type‑III IFN responses and amplified airway inflammation during RSV in DS (preprint evidence), consistent with systemic IFN hypersensitivity in T21 (araya2025interferonsignalingmodulates pages 18-18, galbraith2023multidimensionaldefinitionof pages 1-2)
  • DYRK1A dosage: DYRK1A triplication perturbs neurodevelopment, immune and peripheral phenotypes; therapeutic approaches (small‑molecule inhibitors, EGCG trials, emerging ASO strategies) show promise but mixed preclinical/clinical results and safety/ specificity concerns (llambrich2024pleiotropiceffectsof pages 34-35, araya2025interferonsignalingmodulates pages 1-3)
  • AD biomarkers & pathology in DS: APP dyshomeostasis underlies near‑universal AD neuropathology in DS (amyloid accumulation, altered plaque proteome, tau spread and CAA peptide signatures), motivating trials of anti‑amyloid and other targeted therapies in DS populations (araya2025interferonsignalingmodulates pages 1-3, galbraith2023multidimensionaldefinitionof pages 1-2)

Blockquote: Concise, evidence‑linked bullet lines summarizing mechanistic findings (2023–2025) across interferon/JAK signaling, neurodevelopment, glia, mitochondria, DYRK1A and APP/AD biology in Down syndrome; citations point to the aggregated context evidence used.

1) Core pathophysiology - Interferon/JAK–STAT hyperactivation and immune remodeling - Multi-omic profiling of hundreds of individuals with DS defined a chronic IFN-hyperactive state that stratifies clinical phenotypes, including increased cytotoxic T cells, B-cell depletion, monocyte activation, and enriched autoimmunity and congenital heart disease; the authors conclude DS is an interferonopathy partially driven by triplication of IFN receptor genes on Hsa21 (IFNAR1, IFNAR2, IFNGR2, IL10RB). Normalization of IFN signatures with JAK inhibition was shown in a longitudinal DS case (Science Advances, 2023). (galbraith2023multidimensionaldefinitionof pages 1-2) - In DS–AD mouse models, spatial transcriptomics and flow cytometry demonstrate genome-wide IFN program upregulation, disease-associated microglial states, neuronal loss, and that systemic JAK inhibition rescues inflammatory gene expression and improves cognition, directly implicating IFN/JAK–STAT in DS neurodegeneration. (araya2025interferonsignalingmodulates pages 1-3)

  • Neurodevelopmental alterations: neuron–glia lineage balance, circuit formation
  • Human iPSC and fetal studies show 20–50% fewer cortical neurons from birth; impaired neurogenesis with progenitor cell-cycle and differentiation defects, OLIG2 overexpression favoring astrogliogenesis, and persistent deficits in dendritic arborization and spines that disrupt circuit formation. Modulation of pathways such as SHH and experimental silencing of the extra chromosome rescue aspects of neurogenesis in vitro, highlighting targetability of lineage and morphogen programs. (russo2024consequencesoftrisomy pages 17-18)

  • Astrocyte-centric pathology: prenatal shift from neuron to astrocyte differentiation, increased astrocyte numbers and reactive states, and downstream effects on synaptogenesis and excitatory/inhibitory balance link astrocytic dysfunction to cognitive phenotypes. (uguagliati2024astrocyticalterationsand pages 1-2)

  • Neuroinflammation and microglia

  • Disease-associated microglia (DAM-like) states and interferon-responsive microglia are repeatedly observed in DS and DS–AD models; these states associate with neuronal loss and inflammatory transcriptomes and are suppressible by JAK inhibition in vivo. (araya2025interferonsignalingmodulates pages 1-3)

  • Metabolic stress and redox/tryptophan pathways

  • IFN hyperactivation links to tryptophan catabolism and kynurenine pathway remodeling, associating with neurotoxic catabolites and systemic metabolic changes in DS; these features co-segregate with high IFN scores and clinical burden. (galbraith2023multidimensionaldefinitionof pages 1-2)

  • APP dose and Alzheimer-like pathology

  • APP trisomic dose drives early, widespread amyloid pathology in DS; in DS–AD mouse genetics, additional Hsa21 gene dose modifies cognition and inflammatory states while JAK inhibition reduces inflammatory gene expression and improves cognitive outcomes. (araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18)

2) Key molecular players - Genes/Proteins (HGNC): - IFNAR1, IFNAR2, IFNGR2, IL10RB (interferon receptors; dosage on Hsa21) – drive IFN hypersensitivity and JAK–STAT hyperactivation in DS. (galbraith2023multidimensionaldefinitionof pages 1-2) - JAK1/2–STAT axis (signaling mediators downstream of IFN receptors) – targetable; inhibition normalizes IFN signatures and improves neuroinflammatory/cognitive readouts in models. (galbraith2023multidimensionaldefinitionof pages 1-2, araya2025interferonsignalingmodulates pages 1-3) - APP (amyloid precursor protein; Hsa21) – dose effect underpins DS-associated Alzheimer pathology; amyloid deposition is modified by inflammatory and microglial states. (araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18) - OLIG2 (bHLH TF) – overexpression shifts neurogenesis toward gliogenesis; contributes to reduced neuronal output. (russo2024consequencesoftrisomy pages 17-18) - Astrocytic markers (GFAP and others) – upregulated, reflecting increased astrocytogenesis and reactive astrogliosis. (uguagliati2024astrocyticalterationsand pages 1-2)

  • Chemical entities (CHEBI):
  • JAK inhibitors (e.g., tofacitinib class) – systemically reduce IFN-inducible inflammatory programs and improve cognitive endpoints in DS–AD mice. (araya2025interferonsignalingmodulates pages 1-3)

  • Kynurenine pathway metabolites – implicated in IFN-driven metabolic remodeling and neurotoxicity. (galbraith2023multidimensionaldefinitionof pages 1-2)

  • Cell types (CL):

  • Microglia (CL:0000129) – adopt disease-associated and IFN-responsive states; key in synaptic and inflammatory remodeling. (araya2025interferonsignalingmodulates pages 1-3)
  • Astrocytes (CL:0000127) – increased numbers/reactivity; influence neurogenesis, synaptogenesis, and E/I balance. (uguagliati2024astrocyticalterationsand pages 1-2)
  • Neural progenitors (radial glia) – reduced proliferation/dysregulated cell cycle; impaired neuronal output. (russo2024consequencesoftrisomy pages 17-18)

  • Peripheral T and B cells, monocytes – remodeled with high IFN scores in DS blood multi-omics. (galbraith2023multidimensionaldefinitionof pages 1-2)

  • Anatomical locations (UBERON):

  • Cortex (UBERON:0000956), hippocampus (UBERON:0001954), cerebellum (UBERON:0002037) – sites of reduced neurons, altered lineage dynamics, and glial dysregulation in DS; neuroinflammatory signatures and spatial transcriptomic changes in DS–AD mice. (russo2024consequencesoftrisomy pages 17-18, araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18)
  • Blood (UBERON:0000178) – systemic interferonopathy and immune remodeling detectable in multi-omics. (galbraith2023multidimensionaldefinitionof pages 1-2)

3) Biological processes (GO) disrupted - Type I/II interferon signaling (GO:0060337; GO:0060333), response to interferon (GO:0034340) – chronically upregulated; drives systemic and CNS phenotypes; reversed by JAK inhibition. (galbraith2023multidimensionaldefinitionof pages 1-2, araya2025interferonsignalingmodulates pages 1-3) - JAK–STAT cascade (GO:0007259) – aberrant activation downstream of IFN receptors; targetable with JAK inhibitors. (galbraith2023multidimensionaldefinitionof pages 1-2, araya2025interferonsignalingmodulates pages 1-3) - Neurogenesis and neuron differentiation (GO:0022008; GO:0030182) – reduced neuronal output; lineage skewing to astrocytes (gliogenesis, GO:0014002). (russo2024consequencesoftrisomy pages 17-18, uguagliati2024astrocyticalterationsand pages 1-2) - Synapse organization and dendrite development (GO:0050808; GO:0016358) – persistent dendritic/spine deficits and circuit disruption. (russo2024consequencesoftrisomy pages 17-18) - Immune effector processes and microglial activation (GO:0002252; GO:0001774) – DAM-like and IFN-responsive microglia in DS brain; suppressed by JAK inhibition. (araya2025interferonsignalingmodulates pages 1-3) - Tryptophan metabolic process to kynurenine (GO:0006586) – IFN-associated metabolic remodeling linked to neurotoxic catabolites. (galbraith2023multidimensionaldefinitionof pages 1-2)

4) Cellular components (GO) - Plasma membrane IFN receptor complexes (GO:0005886 context; specific receptor complexes) – dosage increased (IFNAR1/2, IFNGR2, IL10RB) with downstream JAK–STAT activation. (galbraith2023multidimensionaldefinitionof pages 1-2) - Synapse (GO:0045202) and postsynapse (GO:0098794) – affected by dendritic/spine and microglial-mediated remodeling. (russo2024consequencesoftrisomy pages 17-18, araya2025interferonsignalingmodulates pages 1-3) - Microglial cell soma/processes within brain parenchyma – spatially enriched IFN/inflammatory states in DS–AD models. (araya2025interferonsignalingmodulates pages 1-3)

5) Disease progression (sequence of events) - Genetic trigger: trisomy 21 → dosage increase of Hsa21 genes (including IFN receptor subunits and APP). (galbraith2023multidimensionaldefinitionof pages 1-2, araya2025interferonsignalingmodulates pages 1-3) - Early development: progenitor cell-cycle and differentiation defects; neuron-to-astrocyte shift; reduced neuronal output and synaptic maturation → altered circuits from prenatal/early postnatal stages. (russo2024consequencesoftrisomy pages 17-18, uguagliati2024astrocyticalterationsand pages 1-2) - Systemic immune milieu: chronic IFN hyperactivation with immune remodeling and metabolic (kynurenine) changes detectable in blood; clinical associations with congenital heart disease and autoimmunity. (galbraith2023multidimensionaldefinitionof pages 1-2) - CNS inflammation: interferon-responsive microglia and DAM-like states, astrocyte reactivity, and neuronal loss; these inflammatory programs are modulable by JAK inhibition. (araya2025interferonsignalingmodulates pages 1-3) - AD emergence: APP dose accelerates amyloid pathology; IFN/microglial states and broader trisomic gene dose modify progression and cognition; JAK inhibition improves inflammatory signatures and cognitive performance in DS–AD models. (araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18)

6) Phenotypic manifestations (HP terms) linked to mechanisms - Intellectual disability (HP:0001249) – linked to reduced neurogenesis, dendrite/spine deficits, and astrocyte/microglia dysregulation. (russo2024consequencesoftrisomy pages 17-18, uguagliati2024astrocyticalterationsand pages 1-2) - Autoimmunity and immune dysregulation (HP:0002960 aggregate) – associated with high IFN scores and immune remodeling. (galbraith2023multidimensionaldefinitionof pages 1-2) - Early-onset Alzheimer disease pathology (HP:0002511) – driven by APP dose, with microglial/IFN modulation of progression; cognitive decline in DS–AD models is rescueable with JAK inhibition. (araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18)

Current applications and real-world implementations - JAK inhibition as immunomodulation in DS: - Blood multi-omics in people with DS demonstrate normalization of IFN signatures in a longitudinal case under JAK inhibition, motivating clinical testing of JAK inhibitors for DS immune and inflammatory complications (Science Advances, 2023; DOI: 10.1126/sciadv.adg6218). (galbraith2023multidimensionaldefinitionof pages 1-2) - In DS–AD mouse models, systemic JAK inhibition decreased inflammatory gene expression and improved cognition, supporting translational rationale for modulating IFN/JAK–STAT in DS-associated neurodegeneration (iScience, 2025; DOI: 10.1016/j.isci.2025.113130). (araya2025interferonsignalingmodulates pages 1-3)

Expert opinions and analysis (authoritative sources) - “DS displays chronic hyperactivation of interferon signaling … high interferon activity associates with a distinct proinflammatory phenotype” and “JAK inhibition normalizes interferon signatures with therapeutic benefit in DS.” (Science Advances, 2023). (galbraith2023multidimensionaldefinitionof pages 1-2) - Preclinical DS–AD work integrates spatial transcriptomics, immune cytometry, and behavioral readouts to conclude that IFN/JAK–STAT actively modulates pathology and cognition, positioning JAK inhibitors as candidate disease-modifying agents in DS–AD (iScience, 2025). (araya2025interferonsignalingmodulates pages 1-3) - Neurodevelopmental consensus (Nature Reviews Neuroscience, 2024): trisomy 21 disrupts neurogenesis and lineages (e.g., OLIG2-driven gliogenesis) and yields lasting dendritic/synaptic deficits; mechanistic rescue in vitro by morphogen/epigenetic interventions highlights tractable pathways. (russo2024consequencesoftrisomy pages 17-18)

Relevant statistics and data points from recent studies - Multi-omic stratification by interferon score in DS identified strongest peripheral immune remodeling (↑ cytotoxic T cells, B-cell depletion, monocyte activation) in individuals with highest IFN activity; IFN hyperactivation co-segregated with congenital heart disease and autoimmunity (Science Advances, 2023). (galbraith2023multidimensionaldefinitionof pages 1-2) - In DS–AD mice, JAK inhibition reduced brain inflammatory transcriptomes and improved cognition compared with vehicle, linking pathway suppression to functional benefit (iScience, 2025). (araya2025interferonsignalingmodulates pages 1-3)

Evidence items (primary literature, with quotes when available) - “Individuals with Down syndrome (DS) display chronic hyperactivation of interferon signaling… Interferon hyperactivity associates with a distinct proinflammatory phenotype… [and] a longitudinal case study demonstrated that JAK inhibition normalizes interferon signatures with therapeutic benefit in DS.” Science Advances (Jun 2023). (galbraith2023multidimensionaldefinitionof pages 1-2) - “Spatial transcriptomics revealed genome-wide changes dominated by upregulated interferon signatures… Systemic JAK inhibition… rescued gene expression changes and improved cognition,” in DS–AD mouse models. iScience (Aug 2025). (araya2025interferonsignalingmodulates pages 1-3) - “Reduced neurogenesis, progenitor cell-cycle disruption… OLIG2 overexpression… persistent dendritic/spine deficits” summarized for DS brain development. Nature Reviews Neuroscience (Oct 2024). (russo2024consequencesoftrisomy pages 17-18) - “Shift from neuron to astrocyte differentiation… increased astrocyte numbers… detrimental consequences for brain development,” with impacts on synaptogenesis and E/I balance. Cells (Dec 2024). (uguagliati2024astrocyticalterationsand pages 1-2)

Ontology-aligned annotations - Genes/Proteins (HGNC): IFNAR1 (HGNC:5433), IFNAR2 (HGNC:5434), IFNGR2 (HGNC:5437), IL10RB (HGNC:5961), JAK1 (HGNC:6190), JAK2 (HGNC:6192), STAT1 (HGNC:11362), APP (HGNC:620) - Biological Process (GO): type I interferon signaling (GO:0060337); JAK–STAT cascade (GO:0007259); neurogenesis (GO:0022008); gliogenesis (GO:0014002); synapse organization (GO:0050808); tryptophan metabolic process (GO:0006586) - Cellular Component (GO): plasma membrane receptor complex; synapse (GO:0045202); postsynapse (GO:0098794) - Phenotype (HPO): Intellectual disability (HP:0001249); Autoimmunity (HP:0002960); Early-onset Alzheimer disease (HP:0002511) - Cell Types (CL): Microglia (CL:0000129); Astrocyte (CL:0000127); Neural progenitor/radial glia (CL:0002320 subset) - Anatomical (UBERON): Cerebral cortex (UBERON:0000956); Hippocampus (UBERON:0001954); Cerebellum (UBERON:0002037); Blood (UBERON:0000178) - Chemicals (CHEBI): JAK inhibitor (class); kynurenine (CHEBI:30753)

Notes on scope and limitations - Specific complement pathway and cerebrovascular amyloid peptide signatures (CAA) in DS, as well as detailed tau-spread patterns, are rapidly evolving research areas; while supported by recent literature, such details are not fully represented in the evidence extracted here and warrant targeted review of those primary studies for integration. (araya2025interferonsignalingmodulates pages 17-18)

References (URLs and publication dates where available) - Galbraith MD et al. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Science Advances. 2023-06. https://doi.org/10.1126/sciadv.adg6218 (galbraith2023multidimensionaldefinitionof pages 1-2) - Araya P et al. Interferon signaling modulates Down syndrome–associated Alzheimer’s disease pathology in a mouse model. iScience. 2025-08. https://doi.org/10.1016/j.isci.2025.113130 (araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18) - Russo ML, Sousa AMM, Bhattacharyya A. Consequences of trisomy 21 for brain development in Down syndrome. Nature Reviews Neuroscience. 2024-10. https://doi.org/10.1038/s41583-024-00866-2 (russo2024consequencesoftrisomy pages 17-18) - Uguagliati B, Grilli M. Astrocytic Alterations and Dysfunction in Down Syndrome. Cells. 2024-12. https://doi.org/10.3390/cells13242037 (uguagliati2024astrocyticalterationsand pages 1-2)

Cited source IDs: (galbraith2023multidimensionaldefinitionof pages 1-2, araya2025interferonsignalingmodulates pages 1-3, araya2025interferonsignalingmodulates pages 17-18, russo2024consequencesoftrisomy pages 17-18, uguagliati2024astrocyticalterationsand pages 1-2)

References

  1. (galbraith2023multidimensionaldefinitionof pages 1-2): Matthew D. Galbraith, Angela L. Rachubinski, Keith P. Smith, Paula Araya, Katherine A. Waugh, Belinda Enriquez-Estrada, Kayleigh Worek, Ross E. Granrath, Kohl T. Kinning, Neetha Paul Eduthan, Michael P. Ludwig, Elena W. Y. Hsieh, Kelly D. Sullivan, and Joaquin M. Espinosa. Multidimensional definition of the interferonopathy of down syndrome and its response to jak inhibition. Science Advances, Jun 2023. URL: https://doi.org/10.1126/sciadv.adg6218, doi:10.1126/sciadv.adg6218. This article has 52 citations and is from a highest quality peer-reviewed journal.

  2. (araya2025interferonsignalingmodulates pages 1-3): Paula Araya, Brian F. Niemeyer, Kyndal A. Schade, Lauren N. Dunn, Katherine A. Waugh, Nicolas Busquet, Connie Brindley, Chrisstopher Brown, Caitlin Winkler, Hannah R Lyford, Eleanor C. Britton, Michael P Ludwig, Julie A. Siegenthaler, M. Galbraith, Joaquin M. Espinosa, and Kelly D. Sullivan. Interferon signaling modulates down syndrome-associated alzheimer’s disease pathology in a mouse model. iScience, 28:113130, Aug 2025. URL: https://doi.org/10.1016/j.isci.2025.113130, doi:10.1016/j.isci.2025.113130. This article has 0 citations and is from a peer-reviewed journal.

  3. (araya2025interferonsignalingmodulates pages 17-18): Paula Araya, Brian F. Niemeyer, Kyndal A. Schade, Lauren N. Dunn, Katherine A. Waugh, Nicolas Busquet, Connie Brindley, Chrisstopher Brown, Caitlin Winkler, Hannah R Lyford, Eleanor C. Britton, Michael P Ludwig, Julie A. Siegenthaler, M. Galbraith, Joaquin M. Espinosa, and Kelly D. Sullivan. Interferon signaling modulates down syndrome-associated alzheimer’s disease pathology in a mouse model. iScience, 28:113130, Aug 2025. URL: https://doi.org/10.1016/j.isci.2025.113130, doi:10.1016/j.isci.2025.113130. This article has 0 citations and is from a peer-reviewed journal.

  4. (russo2024consequencesoftrisomy pages 17-18): Matthew L. Russo, André M. M. Sousa, and Anita Bhattacharyya. Consequences of trisomy 21 for brain development in down syndrome. Nature reviews. Neuroscience, 25:740-755, Oct 2024. URL: https://doi.org/10.1038/s41583-024-00866-2, doi:10.1038/s41583-024-00866-2. This article has 21 citations.

  5. (uguagliati2024astrocyticalterationsand pages 1-2): Beatrice Uguagliati and Mariagrazia Grilli. Astrocytic alterations and dysfunction in down syndrome: focus on neurogenesis, synaptogenesis, and neural circuits formation. Cells, 13:2037, Dec 2024. URL: https://doi.org/10.3390/cells13242037, doi:10.3390/cells13242037. This article has 3 citations and is from a poor quality or predatory journal.

  6. (risgaard2025molecularandcellular pages 31-33): Ryan D. Risgaard, Kalpana Hanthanan Arachchilage, Sara A. Knaack, Masoumeh Hosseini, Rachel J. Chen, Pubudu Kumarage, Danielle K. Schmidt, Xiang Huang, Jie Sheng, Carlos J. Wang, Elisa Giusti, Shuang Liu, Su-Chun Zhang, Daifeng Wang, Anita Bhattacharyya, and Andre M. M. Sousa. Molecular and cellular processes disrupted in the early postnatal down syndrome prefrontal cortex. bioRxiv, Jul 2025. URL: https://doi.org/10.1101/2025.06.30.662385, doi:10.1101/2025.06.30.662385. This article has 3 citations and is from a poor quality or predatory journal.

  7. (araya2025interferonsignalingmodulates pages 18-18): Paula Araya, Brian F. Niemeyer, Kyndal A. Schade, Lauren N. Dunn, Katherine A. Waugh, Nicolas Busquet, Connie Brindley, Chrisstopher Brown, Caitlin Winkler, Hannah R Lyford, Eleanor C. Britton, Michael P Ludwig, Julie A. Siegenthaler, M. Galbraith, Joaquin M. Espinosa, and Kelly D. Sullivan. Interferon signaling modulates down syndrome-associated alzheimer’s disease pathology in a mouse model. iScience, 28:113130, Aug 2025. URL: https://doi.org/10.1016/j.isci.2025.113130, doi:10.1016/j.isci.2025.113130. This article has 0 citations and is from a peer-reviewed journal.

  8. (llambrich2024pleiotropiceffectsof pages 34-35): Sergi Llambrich, Birger Tielemans, Ellen Saliën, Marta Atzori, Kaat Wouters, Vicky Van Bulck, Mark Platt, Laure Vanherp, Nuria Gallego Fernandez, Laura Grau de la Fuente, Harish Poptani, Lieve Verlinden, Uwe Himmelreich, Anca Croitor, Catia Attanasio, Zsuzsanna Callaerts-Vegh, Willy Gsell, Neus Martínez-Abadías, and Greetje Vande Velde. Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a down syndrome mouse model. eLife, Mar 2024. URL: https://doi.org/10.7554/elife.89763.3, doi:10.7554/elife.89763.3. This article has 4 citations and is from a domain leading peer-reviewed journal.